Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Travere Therapeutics stock | $25.23

Learn how to easily invest in Travere Therapeutics stock.

Travere Therapeutics Inc is a biotechnology business based in the US. Travere Therapeutics shares (TVTX) are listed on the NASDAQ and all prices are listed in US Dollars. Travere Therapeutics employs 262 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Travere Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TVTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Travere Therapeutics stock price (NASDAQ: TVTX)

Use our graph to track the performance of TVTX stocks over time.

Travere Therapeutics shares at a glance

Information last updated 2021-10-16.
Latest market close$25.23
52-week range$12.75 - $33.09
50-day moving average $23.80
200-day moving average $19.62
Wall St. target price$32.71
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.33

Buy Travere Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Travere Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Travere Therapeutics price performance over time

Historical closes compared with the close of $25.23 from 2021-10-21

1 week (2021-10-15) 2.98%
1 month (2021-09-23) 0.80%
3 months (2021-07-23) 90.70%
6 months (2021-04-23) 4.52%
1 year (2020-10-23) 20.43%
2 years (2019-10-23) 122.88%
3 years (2018-10-23) 25.43
5 years (2016-10-21) 22.59%

Travere Therapeutics financials

Revenue TTM $204.1 million
Gross profit TTM $192.2 million
Return on assets TTM -9.85%
Return on equity TTM -72.83%
Profit margin -116.12%
Book value $5.47
Market capitalisation $1.5 billion

TTM: trailing 12 months

Shorting Travere Therapeutics shares

There are currently 6.5 million Travere Therapeutics shares held short by investors – that's known as Travere Therapeutics's "short interest". This figure is 5.5% down from 6.9 million last month.

There are a few different ways that this level of interest in shorting Travere Therapeutics shares can be evaluated.

Travere Therapeutics's "short interest ratio" (SIR)

Travere Therapeutics's "short interest ratio" (SIR) is the quantity of Travere Therapeutics shares currently shorted divided by the average quantity of Travere Therapeutics shares traded daily (recently around 818733.83458647). Travere Therapeutics's SIR currently stands at 7.98. In other words for every 100,000 Travere Therapeutics shares traded daily on the market, roughly 7980 shares are currently held short.

However Travere Therapeutics's short interest can also be evaluated against the total number of Travere Therapeutics shares, or, against the total number of tradable Travere Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Travere Therapeutics's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Travere Therapeutics shares in existence, roughly 110 shares are currently held short) or 0.1554% of the tradable shares (for every 100,000 tradable Travere Therapeutics shares, roughly 155 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Travere Therapeutics.

Find out more about how you can short Travere Therapeutics stock.

Travere Therapeutics share dividends

We're not expecting Travere Therapeutics to pay a dividend over the next 12 months.

Have Travere Therapeutics's shares ever split?

Travere Therapeutics's shares were split on a 1:9 basis on 7 November 2011. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Travere Therapeutics shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Travere Therapeutics shares which in turn could have impacted Travere Therapeutics's share price.

Travere Therapeutics share price volatility

Over the last 12 months, Travere Therapeutics's shares have ranged in value from as little as $12.75 up to $33.0899. A popular way to gauge a stock's volatility is its "beta".

TVTX.US volatility(beta: 0.71)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Travere Therapeutics's is 0.7132. This would suggest that Travere Therapeutics's shares are less volatile than average (for this exchange).

Travere Therapeutics overview

Travere Therapeutics, Inc. , a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc.

Frequently asked questions

What percentage of Travere Therapeutics is owned by insiders or institutions?
Currently 0.801% of Travere Therapeutics shares are held by insiders and 107.686% by institutions.
How many people work for Travere Therapeutics?
Latest data suggests 262 work at Travere Therapeutics.
When does the fiscal year end for Travere Therapeutics?
Travere Therapeutics's fiscal year ends in December.
Where is Travere Therapeutics based?
Travere Therapeutics's address is: 3611 Valley Centre Drive, San Diego, CA, United States, 92130
What is Travere Therapeutics's ISIN number?
Travere Therapeutics's international securities identification number is: US89422G1076

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site